BIONOMICS ANXIOLYTIC BNC210 ‘EFFECTIVE IN 3 ANIMAL SPECIES’
September 3rd 2008 12:47
Monday September 1, 2008
Daily news on ASX-listed biotechnology companies
* BIO-SPRING: BDI-20 UP 14.3%, ALL ORDS UP 3.2%; BIG CAPS UP 29.4%
* ASX DOWN, BIOTECHS UP: POLARTECH UP 22%, CIRCADIAN DOWN 5%
* BIONOMICS ANXIOLYTIC BNC210 ‘EFFECTIVE IN 3 ANIMAL SPECIES’
* FDA APPROVES CYTOPIA TUMOR TRIAL; MULTIPLE MYELOMA DELAYED
* BETA IPO TO RAISE $5m TO STUDY TOCOTRIENOL FOR BREAST CANCER
* AVANTOGEN’S HAWAII BIO TRIALS DENGUE VACCINE WITH US ARMY
* COMPUMEDICS PROFIT UP 515% TO $756k ON REVENUE UP 5%
* NEURODISCOVERY APPOINTS DR CHRIS MOYSES DIRECTOR
* COGSTATE APPOINTS TONY PANTHER ACTING COMPANY SECRETARY
* BIOPROSPECT APPOINTS 3 DIRECTORS
* AUSBIOTECH GOLD COAST INVESTMENT SUMMIT
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
BIONOMICS
Bionomics has told an international congress that BNC210 is effective in models of anxiety in three different animal species.
Bionomics told the 2008 European College of Neuropsychopharmacology Congress in Barcelona that its lead drug was “safe and well tolerated at doses 10,000 times the minimum effective dose”.
The company said it had tested whether BNC210 could decrease the duration of distress-induced vocalizations from guinea pig pups on separation from their mothers.
This model has been validated as a predictor of anxiolytic (anxiety-reducing) activity for a broad range of compound classes.
Bionomics said previous findings had shown that BNC210 reduced anxiety in mice and rats exposed to stresses.
Bionomics project leader Dr Sue O’Connor said that compared to untreated pups, “those given BNC210 uttered distress calls for a shorter time, a clear demonstration of the anxiolytic activity of BNC210”.
Bionomics said the anxiolytic effect of a single dose of BNC210 in mice, lasted for at least six hours, whereas the same dose of diazepam was effective for about three hours.
In addition, treatment with BNC210 did not cause the side effects of sedation, memory impairment and addiction that are associated with diazepam treatment.
The company said that ongoing toxicology studies had shown BNC210 to be safe in both rats and dogs at doses up to 1,000 mg/kg.
Bionomics said tests of repeated doses of BNC210 had begun and results would be included in a submission for regulatory approval for human trials of BNC210 next year.
Bionomics was up half a cent or 1.45 percent to 35 cents.
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 20 |
| Vote |
Shared on
Add To: 
Subscribe to this blog
